Li X - Search Results

1

Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.

Li X, Wetherilt CS, Krishnamurti U, Yang J, Ma Y, Styblo TM, Meisel JL, Peng L, Siddiqui MT, Cohen C, Aneja R. Li X, et al. Am J Clin Pathol. 2016 Oct;146(4):496-502. doi: 10.1093/ajcp/aqw134. Am J Clin Pathol. 2016. PMID: 27686176

2

Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers.

Pannu V, Mittal K, Cantuaria G, Reid MD, Li X, Donthamsetty S, McBride M, Klimov S, Osan R, Gupta MV, Rida PC, Aneja R. Pannu V, et al. Among authors: li x. Oncotarget. 2015 Apr 30;6(12):10487-97. doi: 10.18632/oncotarget.3402. Oncotarget. 2015. PMID: 25868856 Free PMC article.

3

GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.

Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, Li XB. Davis DG, et al. Hum Pathol. 2016 Jan;47(1):26-31. doi: 10.1016/j.humpath.2015.09.015. Epub 2015 Sep 30. Hum Pathol. 2016. PMID: 26527523

4

Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.

Tade FI, Cohen MA, Styblo TM, Odewole OA, Holbrook AI, Newell MS, Savir-Baruch B, Li X, Goodman MM, Nye JA, Schuster DM. Tade FI, et al. Among authors: li x. J Nucl Med. 2016 Sep;57(9):1357-63. doi: 10.2967/jnumed.115.171389. Epub 2016 Apr 7. J Nucl Med. 2016. PMID: 27056619 Free article.

5

Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.

Martinez AP, Cohen C, Hanley KZ, Li XB. Martinez AP, et al. Arch Pathol Lab Med. 2016 Jul;140(7):686-9. doi: 10.5858/arpa.2015-0238-OA. Epub 2016 Apr 26. Arch Pathol Lab Med. 2016. PMID: 27116088 Free article.

6

Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Li XB, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O'Regan R, Aneja R. Li XB, et al. Am J Clin Pathol. 2016 Jun;145(6):871-8. doi: 10.1093/ajcp/aqw045. Epub 2016 Jun 12. Am J Clin Pathol. 2016. PMID: 27298399

7

Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.

Wright N, Rida P, Krishnamurti U, Li X, Aneja R. Wright N, et al. Among authors: li x. Front Biosci (Landmark Ed). 2017 Jan 1;22(2):193-211. doi: 10.2741/4481. Front Biosci (Landmark Ed). 2017. PMID: 27814611 Free article. Review.

8

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.

Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL. Li X, et al. Breast Cancer Res Treat. 2017 Jan;161(2):279-287. doi: 10.1007/s10549-016-4059-6. Epub 2016 Nov 25. Breast Cancer Res Treat. 2017. PMID: 27888421

9

Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations.

Wright N, Xia J, Cantuaria G, Klimov S, Jones M, Neema P, Il'yasova D, Krishnamurti U, Li X, Reid MD, Gupta M, Rida PC, Osan R, Aneja R. Wright N, et al. Among authors: li x. PLoS One. 2017 Jan 13;12(1):e0170095. doi: 10.1371/journal.pone.0170095. eCollection 2017. PLoS One. 2017. PMID: 28085947 Free PMC article.

10

Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.

Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X. Krishnamurti U, et al. Among authors: li x. Hum Pathol. 2017 Jun;64:7-12. doi: 10.1016/j.humpath.2017.01.004. Epub 2017 Jan 30. Hum Pathol. 2017. PMID: 28153508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180,624 results

Search Page

Filters